[Effects of combined application of xuezhikang capsule with hypotensive drugs on arterial compliance and smoothness of the dynamic blood pressure]
- PMID: 20681273
[Effects of combined application of xuezhikang capsule with hypotensive drugs on arterial compliance and smoothness of the dynamic blood pressure]
Abstract
Objective: To investigate the effects of combined application of Xuezhikang Capsule (XZK) and hypotensive drugs on the dynamic blood pressure (DBP), pulse pressure index (PPI), pulse wave velocity (PWV) and smoothness index (SI), and to study the relationship between SI and related factors (age, BP, dynamic PPI, and vascular elasticity).
Methods: One hundred and ten patients with essential hypertension were randomly assigned to 2 groups: 54 in the control group and 56 in the treated group. Both were treated with hypertensive drugs, but with oral medication of XZK given additionally to the treated group at the dose of 60 mg, twice a day. PWV and DBP were measured before treatment and at the terminal of a 6-month treatment. Meantime, the 24-h average systolic and diastolic pressures were recorded to calculate the 24-h dynamic pulse pressure (24 hPP), PPI, SI of systolic and diastolic blood pressure (SISBP and SIDBP) for comparing the changes between groups and analyzing the SI related factors.
Results: All patients' blood pressure levels were well controlled; after a 6-month treatment, the PP and PPI in the treated group were 45 +/- 8 mm Hg and 0.35 +/- 0.08 respectively, which were significantly lower than those in the control group (51 +/- 10 mm Hg and 0.38 +/- 0.05, P < 0.05); while SISBP and SIDBP in the treated group were higher than those in the control group (1.37 +/- 0.16 vs 1.26 +/- 0.20, P < 0.01; and 1.28 +/- 0.14 vs 1.18 +/- 0.23, P < 0.05) respectively; and PWV in the former was significantly lower than that in the latter group (10.4 +/- 3.68 m/s vs 12.5 +/- 4.27 m/s, P < 0.05). Multiple factor stepwise regression analysis showed that the SISBP was negatively correlated with age, PPI and PWV, while the SIDBP was negatively correlated with PPI (P < 0.01).
Conclusion: The combined application of XZK and hypotensive drugs can decrease PP and PPI, improve the endothelial function and arterial elasticity, enhance the efficacy of treatment on SI. After treatment SI shows a significant negative correlation with PPI, PWV and age in patients.
Similar articles
-
Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.Clin Ther. 2009 May;31(5):988-98. doi: 10.1016/j.clinthera.2009.05.020. Clin Ther. 2009. PMID: 19539099 Clinical Trial.
-
Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.Clin Ther. 2007 Sep;29(9):1924-36. doi: 10.1016/j.clinthera.2007.09.018. Clin Ther. 2007. PMID: 18035192 Clinical Trial.
-
Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS).Clin Exp Hypertens. 2010;32(8):491-8. doi: 10.3109/10641961003686427. Clin Exp Hypertens. 2010. PMID: 21091365 Clinical Trial.
-
Systolic blood pressure and pulse pressure: role of 24-h mean values and variability in the determination of organ damage.J Hypertens Suppl. 1999 Dec;17(5):S55-61. J Hypertens Suppl. 1999. PMID: 10706328 Review.
-
Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms.Am J Hypertens. 2005 Jan;18(1 Pt 2):3S-10S. doi: 10.1016/j.amjhyper.2004.10.009. Am J Hypertens. 2005. PMID: 15683725 Review.
Cited by
-
A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases.Acta Pharm Sin B. 2024 Oct;14(10):4228-4242. doi: 10.1016/j.apsb.2024.05.011. Epub 2024 May 11. Acta Pharm Sin B. 2024. PMID: 39525586 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous